Paper20046573
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.
Ramakrishnan MS and 6 others. MAbs, 2009. Cited by 198 papers, by iCite.
Cite this record
ConductScience Library. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Papers, record 20046573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20046573
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Glioma | Major topic |
| Head and Neck Neoplasms | Major topic |
| Nasopharyngeal Neoplasms | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Animals | |
| Antibodies, Monoclonal, Humanized | |
| Clinical Trials, Phase II as Topic | |
| Cuba | |
| Humans | |
| India | |
| Middle Aged |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | Background | ClinicalTrials.gov | |
| NCT04456322 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | Background | ClinicalTrials.gov |
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17367263 | Incidence and management of cutaneous toxicities associated with cetuximab. | Expert Opin Drug Saf | 2007 | https://conductscience.org/library/papers/17367263 | PubMed |
| 2 | 17827980 | Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab. | Cancer Biol Ther | 2007 | https://conductscience.org/library/papers/17827980 | PubMed |
| 3 | 14701780 | Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/14701780 | PubMed |
| 4 | 18337605 | EGFR antagonists in cancer treatment. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18337605 | PubMed |
| 5 | 15117987 | Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/15117987 | PubMed |
| 6 | 16249358 | Nimotuzumab: evidence of clinical benefit without rash. | Oncologist | 2005 | https://conductscience.org/library/papers/16249358 | PubMed |
| 7 | 15950538 | Recent developments related to the EGFR as a target for cancer chemotherapy. | Curr Opin Pharmacol | 2005 | https://conductscience.org/library/papers/15950538 | PubMed |
| 8 | 17010747 | Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. | J Am Acad Dermatol | 2006 | https://conductscience.org/library/papers/17010747 | PubMed |
| 9 | 12237899 | Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. | Int J Cancer | 2002 | https://conductscience.org/library/papers/12237899 | PubMed |
| 10 | 17159497 | Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. | Anticancer Drugs | 2007 | https://conductscience.org/library/papers/17159497 | PubMed |
| 11 | 16467544 | Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16467544 | PubMed |
| 12 | 15864276 | ERBB receptors and cancer: the complexity of targeted inhibitors. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/15864276 | PubMed |
| 13 | 15059649 | Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. | Cancer Treat Rev | 2004 | https://conductscience.org/library/papers/15059649 | PubMed |
| 14 | 1400622 | A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. | J Cell Biochem | 1992 | https://conductscience.org/library/papers/1400622 | PubMed |
| 15 | 18158788 | Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. | Hybridoma (Larchmt) | 2007 | https://conductscience.org/library/papers/18158788 | PubMed |
| 16 | 9154469 | Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. | Immunotechnology | 1997 | https://conductscience.org/library/papers/9154469 | PubMed |
| 17 | 1728407 | A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. | Cancer Res | 1992 | https://conductscience.org/library/papers/1728407 | PubMed |
Cited by115
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 198 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41929496 | Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient. | Front Immunol | 2026 | https://conductscience.org/library/papers/41929496 | PubMed |
| 41916997 | Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/41916997 | PubMed |
| 41618610 | Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy. | J Extracell Vesicles | 2026 | https://conductscience.org/library/papers/41618610 | PubMed |
| 41318392 | Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41318392 | PubMed |
| 40881676 | Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations. | Front Immunol | 2025 | https://conductscience.org/library/papers/40881676 | PubMed |
| 40859900 | EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40859900 | PubMed |
| 40672372 | Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40672372 | PubMed |
| 40335598 | Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer: a multicenter real-world study. | Sci Rep | 2025 | https://conductscience.org/library/papers/40335598 | PubMed |
| 39838362 | Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39838362 | PubMed |
| 39767654 | Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment. | Biomedicines | 2024 | https://conductscience.org/library/papers/39767654 | PubMed |
| 39339232 | Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39339232 | PubMed |
| 38939342 | Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials. | Front Oncol | 2024 | https://conductscience.org/library/papers/38939342 | PubMed |
| 38806289 | Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma. | Cancer Sci | 2024 | https://conductscience.org/library/papers/38806289 | PubMed |
| 38675134 | Evaluation of Advanced Nanomaterials for Cancer Diagnosis and Treatment. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38675134 | PubMed |
| 38549541 | Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis. | Curr Cancer Drug Targets | 2024 | https://conductscience.org/library/papers/38549541 | PubMed |
| 38473402 | Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473402 | PubMed |
| 38090376 | Busting the Breast Cancer with AstraZeneca's Gefitinib. | Adv Pharmacol Pharm Sci | 2023 | https://conductscience.org/library/papers/38090376 | PubMed |
| 37864049 | Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37864049 | PubMed |
| 37724258 | Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. | Med Rev (2021) | 2022 | https://conductscience.org/library/papers/37724258 | PubMed |
| 37458862 | Oncolytic viruses against cancer, promising or delusion? | Med Oncol | 2023 | https://conductscience.org/library/papers/37458862 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20046573
GET https://conductscience.org/api/papers/v1/20046573/cited_by?page=2